The US pharmaceutical company Amgen has evaluated its T-cell engager Imdelltra (tarlatamab) in combination with AstraZeneca’s Imfinzi (durvalumab), reporting strikingly positive results in a phase III trial.
The treatment was given as first-line maintenance therapy to patients with extensive-stage small cell lung cancer (SCLC) whose disease had not progressed following initial treatment with Imfinzi and chemotherapy.
BREAKING